• Publications
  • Influence
Inflammation, atherosclerosis, and coronary artery disease.
Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome.
Based on the preliminary results, introduction of low-dose aspirin therapy during ovulation induction for the prevention of OHSS in high-risk patients should be considered. Expand
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like
It is suggested that GH-RH antagonist MZ-5-156 may inhibit the growth of DU-145 human androgen-independent prostate cancers through a reduction in the production and mRNA expression of IGF-II by the tumor tissue. Expand
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Preliminary studies in animal models of breast and prostate cancers showed that AN-238 is less toxic than AN-201 and more potent in inhibiting tumor growth and both compounds were found to suppress a stimulated growth hormone release at nanomolar concentrations. Expand
Endometriosis: harmful survival of an ectopic tissue.
This review summarizes the current knowledge regarding the pathogenesis of endometriosis, including progress made with transgenic animals, and a clinical perspective on the diagnosis and management of this common process. Expand
Handheld articulating laparoscopic instruments driven by robotic technology. First clinical experience in gynecological surgery
A case in which KYMERAX was successfully used during a total laparoscopic hysterectomy, the world’s first human use of the new robotic-driven, articulating, handheld surgical system, is described. Expand
Lamprey Gonadotropin Hormone‐Releasing Hormone‐III has No Selective Follicle‐Stimulating Hormone‐Releasing Effect In Rats
The hypothesis that LGnRH‐III might be the mammalian FSH‐releasing factor is supported but it is demonstrated that it is a weak agonist for the pituitary LHRH receptor and stimulates both gonadotropins in a dose‐dependent fashion. Expand
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
It is indicated that cytotoxic SST analogue AN-238 can be targeted to SSTRs on tumors and produces a powerful inhibition of the growth of Dunning-AT-1 rat prostate cancer at doses that are nontoxic, whereas its cytot toxic component, 2-pyrrolinodoxorubicin, is toxic and ineffective. Expand
Targeted cytotoxic analog of luteinizing hormone‐releasing hormone AN‐207 inhibits the growth of PC‐82 human prostate cancer in nude mice
Receptors for luteinizing hormone‐releasing hormone (LH‐RH) found in prostate cancers might be used for targeting of chemotherapeutic agents. Doxorubicin derivative 2‐pyrrolinodoxorubicin (AN‐201)Expand
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
This study demonstrates that the cytotoxic LH-RH analog AN-207 exerts highly selective effects on the gonadotroph cells containing LH- RH receptors and is less toxic for other cells Conversely, its cytot toxic radical AN-201 nonselectively damages the pituitary cells. Expand